On June 17, 2025 eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, and Signadori Bio, a French biotechnology company developing next-generation cancer therapies, reported a new collaboration to accelerate the development of gene-modified monocyte-derived macrophage cell therapy targeting solid tumours (Press release, Signadori Bio, JUN 17, 2025, View Source [SID1234656408]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Signadori Bio, a Sofinnova Partners-backed spin-out, is advancing a promising gene-modified monocyte therapy platform aimed at overcoming the challenges of treating solid cancers, developed at the Gustave Roussy Institute, one of the world’s leading oncology centres.
Under the agreement, eXmoor Pharma will undertake a comprehensive technology translation and development programme at its Cell & Gene Therapy Centre, supporting Signadori Bio in the critical transition from discovery through to GMP-compliant manufacturing of their lead candidate. eXmoor will also provide an interim Head of CMC to integrate into Signadori Bio’s leadership team and support a structured programme of technology translation, process development and CMC planning.
This collaborative approach is designed to guide the therapy through key development milestones, with a focus on progressing the lead candidate toward GMP-compliant manufacturing and readiness for first-in-human clinical trials.
The partners will operate under a shared decision-making framework, aligning scientific, technical and commercial planning with Signadori Bio’s investment trajectory. The programme is set to transition into full process development with a long-term view toward GMP manufacturing, leveraging eXmoor’s GMP manufacturing capabilities.
Angela Osborne, CEO of eXmoor Pharma, commented:
"We are delighted to partner with Signadori Bio on such a promising and sophisticated cell therapy programme. Their approach to targeting solid tumours with gene-modified monocytes is innovative and well-grounded in translational science. At eXmoor, we are committed to supporting cell and gene therapy pioneers through the complex journey from discovery to clinical impact. This collaboration reflects our shared belief in the potential of advanced therapies to deliver meaningful outcomes for patients."
Matthieu Coutet, CEO of Signadori Bio and Partner at Sofinnova Partners, said:
"Partnering with eXmoor is a decisive step in our mission to bring next-generation monocyte-based therapies to patients with solid tumours. Their deep expertise in early-stage process development and GMP translation is exactly what we need at this critical inflection point. I’m also very pleased to welcome Evelien Stalmeijer as interim Head of CMC. Her leadership and experience will be key as we accelerate our path toward the clinic. We’re excited to work hand-in-hand with a team that understands the complexity and urgency of advancing pioneering science into impactful therapies."